Lucid Diagnostics Inc (LUCD) - Net Assets
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has net assets worth $25.84 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($53.20 Million) and total liabilities ($27.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lucid Diagnostics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.84 Million |
| % of Total Assets | 48.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 26.07 |
Lucid Diagnostics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Lucid Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Lucid Diagnostics Inc for the complete picture of this company's asset base.
Annual Net Assets for Lucid Diagnostics Inc (2018–2024)
The table below shows the annual net assets of Lucid Diagnostics Inc from 2018 to 2024. For live valuation and market cap data, see Lucid Diagnostics Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.39 Million | +333.28% |
| 2023-12-31 | $-2.31 Million | -110.03% |
| 2022-12-31 | $23.05 Million | -57.90% |
| 2021-12-31 | $54.74 Million | +504.93% |
| 2020-12-31 | $-13.52 Million | -154.61% |
| 2019-12-31 | $-5.31 Million | -399.61% |
| 2018-12-31 | $-1.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lucid Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20264008600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $63.00K | 1.17% |
| Other Components | $209.09 Million | 3878.58% |
| Total Equity | $5.39 Million | 100.00% |
Lucid Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Lucid Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sarana Mitra Luas
JK:SMIL
|
$142.90 Million |
|
Den Networks Limited
NSE:DEN
|
$142.98 Million |
|
REDELFI SPA
F:B0Z
|
$143.02 Million |
|
Empro Group Inc. Ordinary shares
NASDAQ:EMPG
|
$143.05 Million |
|
Pulse Seismic Inc
TO:PSD
|
$142.82 Million |
|
Betmakers Technology Group Ltd
AU:BET
|
$142.68 Million |
|
KOMPLETT ASA NK -40
F:GJ60
|
$142.67 Million |
|
Cashbil
JSE:CSB
|
$142.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lucid Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,311,000 to 5,391,000, a change of 7,702,000.
- Net loss of 45,529,000 reduced equity.
- Share repurchases of 447,000,000 reduced equity.
- New share issuances of 29,798,000 increased equity.
- Other comprehensive income increased equity by 18,625,000,000.
- Other factors decreased equity by 18,154,567,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.53 Million | -844.54% |
| Share Repurchases | $447.00 Million | -8291.6% |
| Share Issuances | $29.80 Million | +552.74% |
| Other Comprehensive Income | $18.62 Billion | +345483.21% |
| Other Changes | $-18.15 Billion | -336756.95% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Lucid Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.03 | $1.09 | x |
| 2019-12-31 | $-0.14 | $1.09 | x |
| 2020-12-31 | $-0.37 | $1.09 | x |
| 2021-12-31 | $1.52 | $1.09 | x |
| 2022-12-31 | $0.64 | $1.09 | x |
| 2023-12-31 | $-0.06 | $1.09 | x |
| 2024-12-31 | $0.11 | $1.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lucid Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -844.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1047.61%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 5.70x
- Recent ROE (-844.54%) is below the historical average (-162.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.02 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.89 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.93 Million |
| 2021 | -51.29% | -5615.60% | 0.01x | 1.08x | $-33.55 Million |
| 2022 | -243.72% | -14899.47% | 0.01x | 1.41x | $-58.48 Million |
| 2023 | 0.00% | -2169.11% | 0.09x | 0.00x | $-52.43 Million |
| 2024 | -844.54% | -1047.61% | 0.14x | 5.70x | $-46.07 Million |
Industry Comparison
This section compares Lucid Diagnostics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lucid Diagnostics Inc (LUCD) | $25.84 Million | 0.00% | 1.06x | $142.90 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the… Read more